Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 11/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.37 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ximoprofen SCHEMBL152469 | 1.00 | APP (0.46) | APPESR2PTGS1PTGS2OPRK1 | |
| Ximoprofen SCHEMBL152468 | 1.00 | APP (0.46) | APPESR2PTGS1PTGS2OPRK1 | |
| SCHEMBL2739331 | 0.85 | ESR2 (0.51) | APPESR2HTTKMT2ALMNA | |
| SCHEMBL9643202 | 0.82 | PTGS1 (0.51) | APPESR2PTGS1PTGS2OPRK1 | |
| SCHEMBL11468007 | 0.80 | APP (0.64) | APPPTGS1PTGS2OPRK1HTT | |
| Hexaprofen SCHEMBL2111016 | 0.78 | APP (0.67) | APPPTGS1PTGS2OPRK1HTT | |
| SCHEMBL14620989 | 0.77 | ESR2 (0.55) | ESR2HTTLMNACYP2C9TSHR | |
| SCHEMBL1570533 | 0.77 | ESR2 (0.54) | ESR2KMT2A | |
| SCHEMBL1570534 | 0.77 | ESR2 (0.54) | ESR2KMT2A | |
| SCHEMBL2436189 | 0.76 | APP (0.56) | APPPTGS1PTGS2OPRK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2012-02-02 | — | — | US | claimed |
| EP-2393771-A1 | Method for the synthesis of chiral alpha-aryl propionic acid derivatives | DSM IP Assets B.V. (NL) | 2011-12-14 | — | — | EP | claimed |
| WO-2010089343-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2010-08-12 | — | — | WO | claimed |
| US-20060154954-A1 | Combinations and use of selected pharmaceutically active compounds | ALTANA PHARMA AG (DE) | 2006-07-13 | — | — | US | claimed |
| EP-1599175-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA Pharma AG (DE) | 2005-11-30 | — | — | EP | claimed |
| WO-2005074930-A1 | PHARMACEUTICAL COMBINATIONS OF (S) -PANTOPRAZOLE WITH NSAID OR CORTICOSTEROIDS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | claimed |
| WO-2004071391-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA PHARMA AG (DE) | 2004-08-26 | — | — | WO | claimed |
| EP-1429807-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-06-23 | — | — | EP | claimed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| US-8242146-B2 | Administering ROFLUMILAS and DICLOFENAC; antiinflammatory agents | NYCOMED GMBH (DE) | 2012-08-14 | — | — | US | disclosed |
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2012-02-02 | — | — | US | disclosed |
| EP-2393771-A1 | Method for the synthesis of chiral alpha-aryl propionic acid derivatives | DSM IP Assets B.V. (NL) | 2011-12-14 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1599175-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA Pharma AG (DE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005074930-A1 | PHARMACEUTICAL COMBINATIONS OF (S) -PANTOPRAZOLE WITH NSAID OR CORTICOSTEROIDS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20040242597-A1 | Combination | NYCOMED GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| WO-2004071391-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA PHARMA AG (DE) | 2004-08-26 | — | — | WO | disclosed |
| EP-1429807-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | GRIA1, GRIA3, GRIA2 | APP 1489/4885ESR2 3064/4885PTGS1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.